219 related articles for article (PubMed ID: 28935960)
1. Combined activation of MAP kinase pathway and β-catenin signaling cause deep penetrating nevi.
Yeh I; Lang UE; Durieux E; Tee MK; Jorapur A; Shain AH; Haddad V; Pissaloux D; Chen X; Cerroni L; Judson RL; LeBoit PE; McCalmont TH; Bastian BC; de la Fouchardière A
Nat Commun; 2017 Sep; 8(1):644. PubMed ID: 28935960
[TBL] [Abstract][Full Text] [Related]
2. β-Catenin nuclear expression discriminates deep penetrating nevi from other cutaneous melanocytic tumors.
de la Fouchardière A; Caillot C; Jacquemus J; Durieux E; Houlier A; Haddad V; Pissaloux D
Virchows Arch; 2019 May; 474(5):539-550. PubMed ID: 30756182
[TBL] [Abstract][Full Text] [Related]
3. Combined deep penetrating nevi of the conjunctiva are relatively common lesions characterised by BRAFV600E mutation and activation of the beta catenin pathway: a clinicopathological analysis of 34 lesions.
Šekoranja D; Vergot K; Hawlina G; Pižem J
Br J Ophthalmol; 2020 Jul; 104(7):1016-1021. PubMed ID: 31558492
[TBL] [Abstract][Full Text] [Related]
4. Combination of Congenital and Deep Penetrating Nevus by Acquisition of β-Catenin Activation.
Garrido MC; Nájera L; Navarro A; Huerta V; Garrido E; Rodriguez-Peralto JL; Requena L
Am J Dermatopathol; 2020 Dec; 42(12):948-952. PubMed ID: 32568834
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic Utility of LEF1 Immunohistochemistry in Differentiating Deep Penetrating Nevi From Histologic Mimics.
Raghavan SS; Saleem A; Wang JY; Rieger KE; Brown RA; Novoa RA
Am J Surg Pathol; 2020 Oct; 44(10):1413-1418. PubMed ID: 32520758
[TBL] [Abstract][Full Text] [Related]
6. Molecular analysis of atypical deep penetrating nevus progressing to melanoma.
Isales MC; Khan AU; Zhang B; Compres EV; Kim D; Tan TL; Beaubier N; Gerami P
J Cutan Pathol; 2020 Dec; 47(12):1150-1154. PubMed ID: 32526042
[TBL] [Abstract][Full Text] [Related]
7. Deep-penetrating-nevus-like melanoma arising in patients with familial adenomatous polyposis syndrome.
Russell-Goldman E; MacConaill L; Laga AC; Hanna J
J Cutan Pathol; 2023 Sep; 50(9):801-805. PubMed ID: 36688401
[TBL] [Abstract][Full Text] [Related]
8. NGS-Based Analysis of Atypical Deep Penetrating Nevi.
Manca A; Sini MC; Cesinaro AM; Portelli F; Urso C; Lentini M; Cardia R; Alos L; Cook M; Simi S; Paliogiannis P; De Giorgi V; Cossu A; Palmieri G; Massi D
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34205480
[TBL] [Abstract][Full Text] [Related]
9. Towards diagnostic criteria for malignant deep penetrating melanocytic tumors using single nucleotide polymorphism array and next-generation sequencing.
Ebbelaar CF; Schrader AMR; van Dijk M; Meijers RWJ; de Leng WWJ; Bloem LT; Jansen AML; Blokx WAM;
Mod Pathol; 2022 Aug; 35(8):1110-1120. PubMed ID: 35184152
[TBL] [Abstract][Full Text] [Related]
10. Deep penetrating nevus-like borderline tumors: A unique subset of ambiguous melanocytic tumors with malignant potential and normal cytogenetics.
Magro CM; Abraham RM; Guo R; Li S; Wang X; Proper S; Crowson AN; Mihm M
Eur J Dermatol; 2014; 24(5):594-602. PubMed ID: 25118781
[TBL] [Abstract][Full Text] [Related]
11. PRAME and LEF1 in Combined Deep Penetrating Nevus and Combined Blue Nevus: Utility and Pitfalls.
Vanderbeck K; Rothrock AT; Cho WC; Nagarajan P; Aung PP; Hudgens C; Bassett RL; Ivan D; Prieto VG; Curry JL; Torres-Cabala CA
Am J Dermatopathol; 2023 Aug; 45(8):549-556. PubMed ID: 37462205
[TBL] [Abstract][Full Text] [Related]
12. CDKN2B Loss Promotes Progression from Benign Melanocytic Nevus to Melanoma.
McNeal AS; Liu K; Nakhate V; Natale CA; Duperret EK; Capell BC; Dentchev T; Berger SL; Herlyn M; Seykora JT; Ridky TW
Cancer Discov; 2015 Oct; 5(10):1072-85. PubMed ID: 26183406
[TBL] [Abstract][Full Text] [Related]
13. An Atypical Deep Penetrating Nevus With Mutations in Beta Catenin , BRAFV600E , and IDH1R132C in an 8-Year-Old Boy.
Ireland AM; Wood BA; Whitfield J; Amanuel B; Harvey NT; Mesbah Ardakani N
Am J Dermatopathol; 2022 Aug; 44(8):607-610. PubMed ID: 35385855
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of cell-cycle arrest in Spitz nevi with constitutive activation of the MAP-kinase pathway.
Maldonado JL; Timmerman L; Fridlyand J; Bastian BC
Am J Pathol; 2004 May; 164(5):1783-7. PubMed ID: 15111324
[TBL] [Abstract][Full Text] [Related]
15. Genetic alterations in melanocytic tumors.
Takata M; Saida T
J Dermatol Sci; 2006 Jul; 43(1):1-10. PubMed ID: 16750612
[TBL] [Abstract][Full Text] [Related]
16. Conventional and Atypical Deep Penetrating Nevus, Deep Penetrating Nevus-like Melanoma, and Related Variants.
Gill P; Aung PP
Biology (Basel); 2022 Mar; 11(3):. PubMed ID: 35336833
[TBL] [Abstract][Full Text] [Related]
17. ALK Rearrangements Are Infrequent in Cellular Blue Nevus and Deep Penetrating Nevus.
Dunn ALJ; Gardner JM; Kaley JR; Bellamy W; Shalin SC
Am J Dermatopathol; 2018 Jul; 40(7):469-478. PubMed ID: 29923908
[TBL] [Abstract][Full Text] [Related]
18. [Nuclear beta-catenin localization is not sufficient for canonical Wnt signaling activation in human meianoma cell lines].
Kulikova KV; Posviatenko AV; Gnuchev NV; Georgiev GP; Kibardin AV; Larin SS
Mol Biol (Mosk); 2011; 45(5):884-91. PubMed ID: 22393786
[TBL] [Abstract][Full Text] [Related]
19. PReferentially expressed antigen in MElanoma (PRAME) expression in BRCA1-associated protein (BAP1)-inactivated melanocytic tumors and deep penetrating nevi: A pilot study.
Lopez DR; Forcucci JA; O'Connor H; Maize JC
J Cutan Pathol; 2021 Apr; 48(4):597-600. PubMed ID: 33094849
[No Abstract] [Full Text] [Related]
20. Detection of the BRAF V600E mutation in melanocytic lesions using the ligase detection reaction.
Turner DJ; Zirvi MA; Barany F; Elenitsas R; Seykora J
J Cutan Pathol; 2005 May; 32(5):334-9. PubMed ID: 15811117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
